Kreus, Mervi
Lehtonen, Siri
Hinttala, Reetta
Salonen, Johanna
Porvari, Katja
Kaarteenaho, Riitta
Article History
Received: 21 January 2022
Accepted: 29 July 2022
First Online: 13 August 2022
Declarations
:
: The Ethical Committee of Northern Ostrobothnia Hospital District in Oulu gave a favourable statement of the study protocol (64/2001, amendment 68/2005, 2/2008, amendment 2/2015, amendment 2/2018). Paraffin embedded tissue samples have been approved for research use by National Supervisory Authority for Welfare and Health (Dnro: V/25054/2019 and V/25090/2019). Permission to use death certificates was given by Statistics Finland (Dnro: TK-53-1025-18). For collection of cells, the patients were interviewed before surgery, and all subjects gave their written informed consent. This study was conducted in accordance with the Helsinki Declaration.
: Not applicable.
: JS reports congress fees and travel costs from Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Orion Pharma and Roche, and lecture fees from Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Orion Pharma and Roche outside the submitted work. RK has received lecture fees from Boehringer-Ingelheim and Roche, advisory board fees from MSD and Boehringer-Ingelheim, and virtual congress costs from Novartis and Roche outside of the submitted work. All other authors declared no conflicts of interest.